News | April 04, 2022
USFDA grants priority review to Roche’s Actemra/RoActemra to treat Covid-19
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
The drug is indicated for use in combination with other drugs
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Laglo Soft lotion comes with a unique technology that enhances moisturisation and restructures the skin
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
The company is moving towards complex and more differentiated products
Subscribe To Our Newsletter & Stay Updated
